Skip to main content
SPRB logo

Spruce Biosciences, Inc. (SPRB) Stock: Price, Forecast & Analyst Target

Spruce Biosciences, Inc. (SPRB) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $40.49 (-0.86%), as of the Nov 19, 2026 trading session; market cap $116M.

Educational signal · not a buy or sell recommendation · How to read this

$40.49 −$0.35 (-0.86%) Market Cap $116M

Spruce Biosciences, Inc. · SPRB · NASDAQ

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders. Their lead product candidate, tildacerfont, is being developed for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

Price as of Nov 19, 2026

Key Statistics

27 of 100

MoonshotScore v2 · Spruce Biosciences (SPRB)

Weak
Business Quality Thin (30)
Financial Safety Fragile (13)
Valuation Bubble (18)
Growth Durability Shrinking (7)
Momentum Slipping (36)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet, stalling growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.

  • EPS beat 3 of the last 8 reports
  • Altman Z -3.87 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SPRB (57 recorded, newest six shown)
RecordedScoreBand
26Weak
26Weak
27Weak
27Weak
27Weak
27Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$40.49
Change on the day-0.86%
52-week range$38.06 – $127.90
Market capitalisation$116M—
Shares traded on the day48.1K

Price & events

Other perspectives

Council score for Spruce Biosciences (SPRB): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Weak

Legends Council

0 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Read date unavailable · not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Moderate
ROE Negative
Gross Margin Negative

Read on: Nov 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Spruce Biosciences (SPRB), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Spruce Biosciences, Inc. (SPRB) is listed on NASDAQ. It employs 22 people and is led by Javier Szwarcberg. The market values it at $116M.

2 · Latest results

What do the latest results show for Spruce Biosciences (SPRB)?

Short answer · as of

Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$0$28M$12.87 (diluted)
Q2 FY2026$0-$16M-$6.68 (diluted)
Q1 FY2026$0-$12M-$8.94 (diluted)
Q4 FY2025$0-$15M-$19.11 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Spruce Biosciences (SPRB)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Altman Z -3.87 · Piotroski F 2. Trailing ratios: ROA -54.2% · current ratio 4.83.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -3.87 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Spruce Biosciences (SPRB)?

Short answer · as of

Current published price targets run low $104.00 · high $160.00 · consensus $141.20 · median $149.00 against a quoted price of $40.49 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Spruce Biosciences compare with its peers?

Short answer

Spruce Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
Spruce Biosciences (SPRB) — this page$40.49$116M27

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$104.00 – $160.00
Consensus target
$141.20
Median target
$149.00

Consensus record · Captured .

Measured against a quoted price of $40.49 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 27, 2026

Transactions
2
Identified insiders
2
Purchases
0
Sales
0
Other transactions
2

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SPRB in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SPRB in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Spruce Biosciences (SPRB)?

Read these with our analysis →

What Investors Ask About Spruce Biosciences (SPRB)

These answers are editorial: 1 of these 9 answers is drawn from the SPRB research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SPRB?

SPRB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders.

Is SPRB a good stock to buy?

Stock Expert AI does not rate SPRB buy, sell or hold. Spruce Biosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SPRB stock price today?

The last price recorded for Spruce Biosciences, Inc. (SPRB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SPRB price target?

The analyst consensus price target for Spruce Biosciences, Inc. (SPRB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about SPRB stock?

Analyst coverage of Spruce Biosciences, Inc. (SPRB) is limited, reflecting its status as a clinical-stage biopharmaceutical company. However, analysts generally view the company's focus on rare endocrine disorders as a positive factor, given the high unmet medical needs in these areas.

What are the key factors to evaluate for SPRB?

Spruce Biosciences, Inc. (SPRB) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. This expansion could diversify Spruce Biosciences' pipeline and reduce its reliance on a single product candidate. Not financial advice.

How frequently does SPRB data refresh on this page?

SPRB's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SPRB's recent stock price performance?

Spruce Biosciences, Inc. (SPRB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare endocrine disorders with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SPRB overvalued or undervalued right now?

Spruce Biosciences, Inc. (SPRB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.